• Signing informed consent; ECOG 0-2 points;

• Age over 18 years old, gender is not limited;

• Esophageal squamous cell carcinoma confirmed by pathology or clinically diagnosed by imaging;

• Recurrence of the tumor area after radical surgery or radical chemoradiotherapy; Regional progression of advanced esophageal squamous cell carcinoma after first-line or second-line treatment;

• Clinical staging: regional recurrence (rT0-4N0-3M0-1a) or regional progression (cT0-4N0-3M0-1) (AJCC/UICC esophageal cancer staging (8th edition));

• Tumor lesions can be evaluated;

• Expected survival ≥3 months;

• Major organ function is normal, meeting the following criteria: (i) blood routine examination A.HB ≥90g/L; b.ANC≥1.5×109/L; C. PLT ≥80×109/L; (ii) Biochemical examination: a. ALT/AST≤2.5ULN; b. TBIL≤1.5ULN; c. Plasma Cr≤1.5ULN or creatinine clearance (CCr)≥60ml/min;

• Women of childbearing age must have had a pregnancy within 7 days before starting treatment and the result is negative;

• All enrolled patients should take adequate contraceptive measures throughout the treatment period and 4 weeks after completion;

• no serious hematopoietic function, heart function, endocrine and immune function defects;

• No patients with grade 3 or above other serious medical diseases.